Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Overview of attention for article published in Journal of Clinical Oncology, November 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 6 news outlets
policy: 1 policy source
twitter: 28 X users

googleplus: 1 Google+ user
guideline: 2 clinical guideline sources

Readers on

mendeley: 377 Mendeley

So far, Altmetric has seen 33 X posts from 28 X users, with an upper bound of 223,996 followers.

RT @PLMcCarthyMD: PD-1 Blockade With Pembrolizumab in HL pts post B-Vedotin Failure: Journal of Clinical Oncology: Vol 34, No 31 https://t.…

RT @DrRaulCordoba: The CR rate was 16% (90% CI, 7% to 31%). In addition, 48% of patients achieved a PR, for an ORR of 65% (90% CI, 48% to 7…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 29 additional X posts.